公开(公告)号：WO2008112290A2

公开(公告)日：2008-09-18

申请号：PCT/US2008/003355

申请日：2008-03-12

Applicant: VASGENE THERAPEUTICS, INC. ,  MD ANDERSON CANCER CENTER ,  KRASNOPEROV, Valery ,  GILL, Parkash ,  SOOD, Anil, K.

Inventor： KRASNOPEROV, Valery ,  GILL, Parkash ,  SOOD, Anil, K.

IPC: C07K16/28 ,  C12N15/11 ,  A61K39/395 ,  A61P35/00 ,  C07K16/00

CPC classification number: G01N33/57449 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  G01N2333/715

Abstract: In certain embodiments, this present invention provides compositions, and methods for inhibiting EphB4 activity in ovarian cancer. In other embodiments, the present invention provides methods and compositions for treating ovarian cancer.

Abstract translation: 在某些实施方案中，本发明提供了用于抑制卵巢癌中EphB4活性的组合物和方法。 在其它实施方案中，本发明提供了治疗卵巢癌的方法和组合物。

公开(公告)号：WO2007028110A2

公开(公告)日：2007-03-08

申请号：PCT/US2006/034391

申请日：2006-09-01

Applicant: VASGENE THERAPEUTICS, INC. ,  GILL, Parkash ,  DUARTE, Antonio ,  JIANG, Weidong

Inventor： GILL, Parkash ,  DUARTE, Antonio ,  JIANG, Weidong

CPC classification number: A61K38/1709 ,  G01N33/5064

Abstract: In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (D114) signaling.

Abstract translation: 在某些实施方案中，本发明提供了鉴定和使用δ样4（Dll4）信号传导的激动剂和拮抗剂的方法。

公开(公告)号：WO2006034455A3

公开(公告)日：2006-03-30

申请号：PCT/US2005/034176

申请日：2005-09-23

Applicant: VASGENE THERAPEUTICS, INC. ,  KRASNOPEROV, Valery ,  ZOZULYA, Sergey ,  KERTESZ, Nathalie ,  REDDY, Ramachandra ,  GILL, Parkash

Inventor： KRASNOPEROV, Valery ,  ZOZULYA, Sergey ,  KERTESZ, Nathalie ,  REDDY, Ramachandra ,  GILL, Parkash

IPC: C07K14/705 ,  A61K47/48 ,  A61K38/00

Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.

公开(公告)号：WO2006034455A2

公开(公告)日：2006-03-30

申请号：PCT/US2005034176

申请日：2005-09-23

Applicant: VASGENE THERAPEUTICS INC ,  KRASNOPEROV VALERY ,  ZOZULYA SERGEY ,  KERTESZ NATHALIE ,  REDDY RAMACHANDRA ,  GILL PARKASH

Inventor： KRASNOPEROV VALERY ,  ZOZULYA SERGEY ,  KERTESZ NATHALIE ,  REDDY RAMACHANDRA ,  GILL PARKASH

CPC classification number: A61K38/385 ,  A61K38/00 ,  A61K47/60 ,  C07K14/715

Abstract: In certain embodiments, this present invention provides polypeptide compositions,

Abstract translation: 在某些实施方案中，本发明提供了多肽组合物，

公开(公告)号：WO2023039008A1

公开(公告)日：2023-03-16

申请号：PCT/US2022/042812

申请日：2022-09-07

Applicant: VASGENE THERAPEUTICS INC.

Inventor： COGAN, Jon ,  KRASNOPEROV, Valery

IPC: A61K38/17 ,  G01N33/50 ,  C07K14/705

Abstract: The present invention describes the use of EphrinB2 expression as a biomarker to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual suffering from a platinum resistant metastatic cancer. In one aspect, the invention provides methods to diagnose and select a subject with cancer for treatment using an EphB4-EphrinB2 inhibitor, or an EphB4-EphrinB2 inhibitor in combination with an immune stimulating drug, as front-line therapy for treatment of cancers, for treatment of a number of cancers where standard therapies have been shown to be ineffective, result in relapse, or are not even considered for use due to the type of cancer and related tumors, and/or for treatment of a number of cancers wherein the subject is currently on a course of treatment with an immune stimulating drug.

公开(公告)号：WO2005090406A3

公开(公告)日：2006-12-28

申请号：PCT/US2005008280

申请日：2005-03-11

Applicant: VASGENE THERAPEUTICS INC ,  KRASNOPEROV VALERY ,  ZOZULYA SERGEY ,  KERTESZ NATHALIE ,  REDDY RAMACHANDRA ,  GILL PARKASH

Inventor： KRASNOPEROV VALERY ,  ZOZULYA SERGEY ,  KERTESZ NATHALIE ,  REDDY RAMACHANDRA ,  GILL PARKASH

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  C12N5/20

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/73 ,  C07K2317/75

Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.

Abstract translation: 在某些实施方案中，本发明提供多肽组合物（例如，结合EphB4的抗体及其抗原结合部分）和抑制EphB4活性的方法。 在其它实施方案中，本发明提供了治疗癌症或治疗血管生成相关疾病的方法和组合物。

公开(公告)号：WO2005090406A2

公开(公告)日：2005-09-29

申请号：PCT/US2005/008280

申请日：2005-03-11

Applicant: VASGENE THERAPEUTICS, INC. ,  KRASNOPEROV, Valery ,  ZOZULYA, Sergey ,  KERTESZ, Nathalie ,  REDDY, Ramachandra ,  GILL, Parkash

Inventor： KRASNOPEROV, Valery ,  ZOZULYA, Sergey ,  KERTESZ, Nathalie ,  REDDY, Ramachandra ,  GILL, Parkash

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/73 ,  C07K2317/75

Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.

Abstract translation: 在某些实施方案中，本发明提供多肽组合物（例如，结合EphB4的抗体及其抗原结合部分）和抑制EphB4活性的方法。 在其它实施方案中，本发明提供了治疗癌症或治疗血管生成相关疾病的方法和组合物。

公开(公告)号：WO2004080418A2

公开(公告)日：2004-09-23

申请号：PCT/US2004/007491

申请日：2004-03-12

Applicant: VASGENE THERAPEUTICS, INC. ,  REDDY, Ramachandra ,  GILL, Parkash

Inventor： REDDY, Ramachandra ,  GILL, Parkash

IPC: A61K

CPC classification number: C07K16/2866 ,  C07K14/715 ,  C07K16/30 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315

Abstract: In certain embodiments, this present disclosure provides nucleic acid compounds, compositions, and methods for inhibiting Ephrin B2 or EphB4 expression. In certain embodiments, the present disclosure provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.

Abstract translation: 在某些实施方案中，本公开内容提供用于抑制Ephrin B2或EphB4表达的核酸化合物，组合物和方法。 在某些实施方案中，本公开提供用于治疗癌症或用于治疗血管生成相关疾病的方法和组合物。

公开(公告)号：WO2020190977A1

公开(公告)日：2020-09-24

申请号：PCT/US2020/023215

申请日：2020-03-17

Applicant: VASGENE THERAPEUTICS INC

Inventor： KRASNOPEROV, Valery

IPC: A61K39/00 ,  C07K7/04

Abstract: Compositions and methods are provided for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a polypeptide agent that inhibits EphB4 or EphrinB2 mediated functions. In various embodiments the methods further provide administration of a therapeutically effective amount of an immune checkpoint inhibitor. The present inventors have demonstrated that the synergistic effect of the combination of an EphB4-EphrinB2 inhibitor and checkpoint inhibitor provides superior progression-free survival (PFS) and objective response rates (ORR) patients with various cancers by activating T cell and promoting T cell and NK cell trafficking into the tumor and via migration of immune cells (e.g., CD3 and CD8) into the tumor.

公开(公告)号：WO2009085209A2

公开(公告)日：2009-07-09

申请号：PCT/US2008/013899

申请日：2008-12-19

Applicant: VASGENE THERAPEUTICS, INC. ,  GILL, Parkash ,  LIU, Ren ,  KRASNOPEROV, Valery

Inventor： GILL, Parkash ,  LIU, Ren ,  KRASNOPEROV, Valery

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/22

CPC classification number: C07K16/22 ,  A61K38/177 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/30 ,  G01N33/5011 ,  G01N33/5064 ,  A61K2300/00

Abstract: In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (Dll4) signaling.

Abstract translation: 在某些实施方案中，本发明提供了鉴定和使用δ样4（Dll4）信号传导的激动剂和拮抗剂的方法。